This site is intended for healthcare professionals

Cassava Sciences announces initiation of simufilam in patients with Alzheimer’s disease in a phase III cognition maintenance study.

Read time: 1 mins
Last updated:28th Jun 2021
Published:11th May 2021
Cassava Sciences, Inc.has announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam is a drug candidate that seeks to reduce neurodegeneration and neuroinflammation.
Condition: Alzheimers
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest